| Name | Title | Contact Details |
|---|
Seqirus, part of the CSL Group, is the new global company created from the combined strength and expertise of bioCSL and the influenza vaccines business formerly owned by Novartis. In July 2015, the two businesses joined forces to create Seqirus, now the second largest influenza vaccine company in the world. With extensive research and production expertise and manufacturing plants in the US, UK, Germany and Australia, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally. Seqirus has a workforce of over 2,000 employees, significant manufacturing capacity and a commercial presence in over 20 countries. In Australia and New Zealand, Seqirus markets a comprehensive range of vaccines and speciality pharmaceutical products. It also manufactures products of national significance for Australia, including antivenoms and Q fever vaccine, and supplies diagnostic reagents in the Australasia region. Seqirus cold-chain logistics business ensures the integrity of CSL products, as well as those of our customers, as they are safely delivered across Australia.
Baxter International Inc. is a Fortune 500 American health care company with headquarters in Deerfield, Illinois.
Indiva is a Canadian licensed producer of premium cannabis and cannabis products, and a provider of extraction, manufacturing and refinement services.
Diapharma Group Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Updates, earnings and commercializationListen to the audio recording of our recent shareholder call where we discussed the latest updates, gave an overview of our earnings report and highlighted the commercialization efforts underway at Predictive Onco...